{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:12Z","timestamp":1790205492991,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T00:00:00Z","timestamp":1265673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s00228-009-0783-8","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T09:38:43Z","timestamp":1265621923000},"page":"465-474","source":"Crossref","is-referenced-by-count":63,"title":["Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure\u2014an impact similar to male gender or smoking in schizophrenic patients"],"prefix":"10.1007","volume":"66","author":[{"given":"Roza","family":"Ghotbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buster","family":"Mannheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"\u00d6sby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,9]]},"reference":[{"issue":"12","key":"783_CR1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209\u20131223","journal-title":"N Engl J Med"},{"issue":"2","key":"783_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","volume":"48","author":"KL Bigos","year":"2008","unstructured":"Bigos KL, Pollock BG, Coley KC, del Miller D, Marder SR, Aravagiri M et al (2008) Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48(2):157\u2013165","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"783_CR3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/FTD.0b013e3181633429","volume":"30","author":"CJ Bachmann","year":"2008","unstructured":"Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, Remschmidt H, Theisen FM (2008) Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 30(1):108\u2013112","journal-title":"Ther Drug Monit"},{"issue":"1","key":"783_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","volume":"21","author":"PJ Perry","year":"2001","unstructured":"Perry PJ, Lund BC, Sanger T, Beasley C (2001) Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine trial. J Clin Psychopharmacol 21(1):14\u201320","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"783_CR5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","volume":"25","author":"M Gex-Fabry","year":"2003","unstructured":"Gex-Fabry M, Balant-Gorgia AE, Balant LP (2003) Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25(1):46\u201353","journal-title":"Ther Drug Monit"},{"issue":"1","key":"783_CR6","first-page":"81","volume":"25","author":"K Kassahun","year":"1997","unstructured":"Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A et al (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 25(1):81\u201393","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"783_CR7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.403","volume":"17","author":"K Linnet","year":"2002","unstructured":"Linnet K (2002) Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 17(5):233\u2013238","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"783_CR8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-3565(25)12326-4","volume":"276","author":"BJ Ring","year":"1996","unstructured":"Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ et al (1996) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276(2):658\u2013666","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"783_CR9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychires.2006.10.002","volume":"42","author":"N Bozina","year":"2008","unstructured":"Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L (2008) Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 42(2):89\u201397","journal-title":"J Psychiatr Res"},{"issue":"4","key":"783_CR10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/hep.20131","volume":"39","author":"U Ehmer","year":"2004","unstructured":"Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP (2004) Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39(4):970\u2013977","journal-title":"Hepatology"},{"issue":"14","key":"783_CR11","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1093\/nar\/gnf069","volume":"30","author":"K Lindroos","year":"2002","unstructured":"Lindroos K, Sigurdsson S, Johansson K, Ronnblom L, Syvanen AC (2002) Multiplex SNP genotyping in pooled DNA samples by a four-colour microarray system. Nucleic Acids Res 30(14):e70","journal-title":"Nucleic Acids Res"},{"key":"783_CR12","unstructured":"University of Geneva (2000) Arlequin: a software for population genetics data analysis. Ver 2.000 (computer program). Genetics and Biometry Lab, Department of Anthropology, University of Geneva"},{"issue":"3","key":"783_CR13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","volume":"29","author":"L Citrome","year":"2009","unstructured":"Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG et al (2009) Olanzapine plasma concentrations after treatment with 10, 20, and 40\u00a0mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 29(3):278\u2013283","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"783_CR14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/14656566.1.2.305","volume":"1","author":"BC Lund","year":"2000","unstructured":"Lund BC, Perry PJ (2000) Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opin Pharmacother 1(2):305\u2013323","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"783_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eurpsy.2004.09.009","volume":"20","author":"MC Mauri","year":"2005","unstructured":"Mauri MC, Steinhilber CP, Marino R, Invernizzi E, Fiorentini A, Cerveri G et al (2005) Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 20(1):55\u201360","journal-title":"Eur Psychiatry"},{"issue":"1","key":"783_CR16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","volume":"30","author":"M Nozawa","year":"2008","unstructured":"Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R et al (2008) The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 30(1):35\u201340","journal-title":"Ther Drug Monit"},{"issue":"5","key":"783_CR17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.104.002576","volume":"33","author":"A Mori","year":"2005","unstructured":"Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 33(5):672\u2013675","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"783_CR18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","volume":"63","author":"R Ghotbi","year":"2007","unstructured":"Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63(6):537\u2013546","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"783_CR19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00898.x","volume":"47","author":"C Sachse","year":"1999","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C\u2013>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47(4):445\u2013449","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"783_CR20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.taap.2008.02.020","volume":"230","author":"TJ Erichsen","year":"2008","unstructured":"Erichsen TJ, Ehmer U, Kalthoff S, Lankisch TO, Muller TM, Munzel PA et al (2008) Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol 230(2):252\u2013260","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"783_CR21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00228-007-0438-6","volume":"64","author":"N Djordjevic","year":"2008","unstructured":"Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64(4):381\u2013385","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0783-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0783-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T01:49:37Z","timestamp":1739843377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0783-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0783-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,9]]}}}